Low Molecular Weight Heparin-Catalyzed Inactivation of Factor Xa and Thrombin by Antithrombin III – Effect of Platelet Factor 4

Summary

Low molecular weight (LMW) heparin preparations have unknown distributions of ATIII-binding material, so mean molecular weights as such might bear little information on their anti-factor Xa and anti-thrombin activities, and on the neutralization of these activities by platelet factor 4 (PF4). These properties were investigated in pure systems with proteins of human origin. Pseudo-first order rate constants of inactivation of factor Xa and thrombin by antithrombin III were determined as function of heparin concentration, in the presence of 4.0 mM CaCl₂. Despite a large variation in the mean molecular weights, the ratios of the anti-factor Xa over the anti-thrombin activities were essentially the same for the 4th International Standard for heparin (0.46), the 1st International Standard for LMW heparin (0.32), CY216 (0.42) and enoxaparin (0.50). The ultra LMW heparin CY222 had only a 2-times higher ratio (0.98). Analysis of CY216 subfractions, obtained by gel filtration, showed that the heparin molecules of the upper region of the molecular weight distribution are responsible for the anti-thrombin, but also to a large extent for the anti-factor Xa activities. The results indicate that depolymerization of unfractionated heparin does not result in an increased anti-factor Xa/anti-thrombin ratio, because in the presence of Ca²⁺-ions the rate constants of inactivation of factor Xa are lowered as compared to those of native heparin. PF4-dependent neutralization of anti-factor Xa and anti-thrombin activities of fixed concentrations of the LMW heparins was studied by measuring rate constants as function of PF4 concentration. All anti-thrombin and 50% of the anti-factor Xa activities were readily neutralized. Excess PF4 was required to neutralize another 35-50% of the anti-factor Xa activities. At PF4 levels obtained at maximal release of the content of platelet α-granules, all anti-thrombin and most (≥85%) of the anti-factor Xa activities can be neutralized.

• References

• 1 Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 1968; 21: 89-91
• 2 Choay J. Structure and activity of heparin and its fragments: an overview. Semin Thromb Hemostas 1989; 15: 359-64
• 3 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-32
• 4 Danielsson A, Raub E, Lindahl U, Björk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the accelaration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261: 15467-73
• 5 Thunberg L, Lindahl U, Tengblad A, Laurent TC, Jackson CM. On the molecular-weight-dependence of the anticoagulant activity of heparin. Biochem J 1979; 181: 241-3
• 6 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Söderström G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-41
• 7 Holmer E, Lindahl U, Bôckström G, Thunberg L, Sandberg H, Söderström G, Andersson LO. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-9
• 8 Drouet L, Caen JR. Current perspectives in the treatment of thrombotic disorders. Semin Thromb Hemostas 1989; 15: 111-22
• 9 Messmore HL. Clinical potential of low molecular weight heparins. Semin Thromb Hemostas 1989; 15: 405-8
• 10 Fareed J, Walenga JM, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemostas 1989; 15: 440-63
• 11 Barrowcliffe TW, Shirley YL. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions. Thromb Haemostas 1989; 62: 950-4
• 12 Schoen P, Lindhout T, Willems G, Hemker HC. Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. J Biol Chem 1989; 264: 10002-7
• 13 Speight MO, Griffith MJ. Calcium inhibits the heparin-catalyzed antithrombin III/thrombin reaction by decreasing the apparent binding affinity of heparin for thrombin. Arch Biochem Biophys 1983; 225: 958-63
• 14 Cowan SW, Bakshi EN, Machin KJ, Isaacs NW. Binding of heparin to human platelet factor 4. Biochem J 1986; 234: 485-8
• 15 Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 455-60
• 16 Levine SP, Wohl H. Human platelet factor 4: purification and characterization by affinity chromatography. Purification of human platelet factor 4. J Biol Chem 1976; 251: 324-8
• 17 McLaren KM, Holloway L, Pepper DS. Human platelet factor 4 and tissue mast cells. Thromb Res 1980; 19: 293-7
• 18 Schoen P, Wielders S, Petitou M, Lindhout T. The effect of sulfation on the anticoagulant and antithrombin III-binding properties of a heparin fraction with low affinity for antithrombin III. Thromb Res 1990; 57: 415-23
• 19 Hendrix H, Lindhout T, Mertens K, Engels W, Hemker HC. Activation of human prothrombin by stoichiometric levels of staphylocoagulase. J Biol Chem 1983; 258: 3637-44
• 20 Miller-Andersson M, Gaffney PJ, Seghatchian MJ. Preparation and stability of a highly purified human thrombin standard. Thromb Res 1980; 20: 109-22
• 21 Smith RL. Titration of activated bovine factor X. J Biol Chem 1973; 248: 2418-23
• 22 Chase T, Shaw E. Comparison of the esterase activities of trypsin, plasmin and thrombin on guanidinobenzoate esters. Titration of the enzymes. Biochemistry 1969; 8: 2212-24
• 23 Petitou M, Lormeau JC, Perly B, Berthault P, Bossennec V, Sie P, Choay J. Is there a unique sequence in heparin for interaction with heparin cofactor II? Structural and biological studies of heparinderived oligosaccharides. J Biol Chem 1988; 263: 8685-90
• 24 Höök M, Björk I, Hopwood J, Lindahl U. Anticoagulant activity of heparin; Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 1976; 66: 90-3
• 25 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-7
• 26 Ellis V, Scully MF, Kakkar VV. The relative molecular mass dependence of the anti-factor Xa properties of heparin. Biochem J 1986; 238: 329-33